ArticleEClinicalMedicine2026
Efficacy and safety of sublingual cilostazol and dexborneol for the treatment of acute ischaemic stroke: a randomised phase 2 trial in China.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endovascular treatment has emerged as a cornerstone intervention for acute ischaemic stroke caused by large-vessel occlusion. However, a subset of patients experience futile recanalisation, correlating with unfavourable long-term outcomes. We aimed to investigate the efficacy and safety of Y-6 sublingual tablets (cilostazol and dexborneol) in ischaemic stroke patients with endovascular treatment. Methods: This randomised, double-blind, double-dummy, placebo-controlled phase 2 trial in 33 centres in China prospectively enrolled patients aged 35-80 years, who had ischaemic stroke with large vessel occlusion in the anterior circulation within 24 h of onset, with an NIHSS score 7-25 at randomisation. Participants were randomly assigned (1:1:1:1:1) to the Y-6 high-dose group, Y-6 low-dose group, cilostazol high-dose group, cilostazol low-dose group, and placebo group for 28 days. The modified intention-to-treat analysis included the patients receiving at least one dose of the intervention. The primary efficacy outcome was the 90-day mRS 0-1 score, and the primary safety outcome was symptomatic intracranial haemorrhage at 28 days. The trial has been registered on ClinicalTrials.govNCT06138834. Findings: Between Dec 14, 2023, and Dec 25, 2024, of 300 enrolled Chinese patients, 294 patients were included in the intention-to-treat analysis with 213 (72.4%) male. A favourable functional outcome (mRS 0-1) at 90 days occurred in 25 patients (44.6%) in the Y-6 high-dose group (RR 1.25, 95% confidence interval [CI] 0.79-1.97; p = 0.34), 29 patients (46.0%) in the Y-6 low-dose group (RR 1.29, 95% CI 0.83-2.00; p = 0.25), 25 patients (41.7%) in the cilostazol high-dose group (RR 1.17, 95% CI 0.74-1.85; p = 0.51), 22 patients (37.3%) in the cilostazol low-dose group (RR 1.04, 95% CI 0.64-1.69; p = 0.86), and 20 patients (35.7%) in the placebo group. Symptomatic intracranial haemorrhage at 28 days occurred in 1 patient (1.8%) in the Y-6 high-dose group, 3 patients (4.8%) in the Y-6 low-dose group, 2 patients (3.3%) in the cilostazol high-dose group, 4 patients (6.8%) in the cilostazol low-dose group, and 2 patients (3.6%) in the placebo group. No significant differences in efficacy and safety outcomes were found compared with that in the placebo group. Serious adverse events within 90 days occurred in 14 patients (25.0%) in the Y-6 high-dose group, 18 patients (28.6%) in the Y-6 low-dose group, 18 patients (30.0%) in the cilostazol high-dose group, 24 patients (40.7%) in the cilostazol low-dose group, and 14 patients (25.0%) in the placebo group. Interpretation: Our findings indicate that, for patients with ischaemic stroke undergoing endovascular treatment for large vessel occlusion, Y-6 sublingual tablets (cilostazol and dexborneol) were safe with tolerance. Although the trial did not demonstrate statistically significant efficacy on the primary outcome, the signal toward improved functional outcomes without haemorrhage risk supports the biological plausibility of the intervention and justifies further investigation. Large-scale phase 3 clinical trials are warranted to further this research. Funding: The National Natural Science Foundation of China; Noncommunicable Chronic Diseases-National Science and Technology Major Project; Beijing Municipal Science & Technology Commission; Capital's Funds for Health Improvement and Research; National Key R&D Program of China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.